Replication of prognostic value of novel biomarker CCN1 in validation cohort from DZHK biobank; Exploration of underlying pathophysiology using a proteomics approach

We have identified CCN1 as a novel circulating biomarker in cardiovascular patients with Acute Coronary Syndromes and now also in patients with Dilated Cardiomyopathy. In both clinical settings, CCN1 constitutes an independent prognostic biomarker to predict all-cause mortality. We now aim to replicate our findings measuring CCN1 by means of EIA assay technology in a validation cohort from the DZHK biobank. In order to gain novel insights into what disease process this biomarker reflects and how this impacts on mortality, we aim to perform a comprehensive analysis of proteins involved. To this end, we plan to perform proteomic analyses using the Olink Bioscience platform in 410 patients from the DZHK biobank and correlate CCN1 and pertinent proteins identified with this approach with all-cause mortality in these patients.